Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
Given the increasing use of combination therapy with multiple monoclonal antibodies (mAbs), there is a clinical need for multiplexing assays. For the frequently co-administered anti-human epidermal growth factor receptor 2 (HER2) mAbs trastuzumab and pertuzumab, we developed a high-throughput and ro...
Main Authors: | Sandor Schokker, Fabrizia Fusetti, Francesco Bonardi, Remco J. Molenaar, Ron A.A. Mathôt, Hanneke W.M. van Laarhoven |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2020.1795492 |
Similar Items
-
Pertuzumab and trastuzumab: the rationale way to synergy
by: SANDRINE RICHARD, et al.
Published: (2016-01-01) -
Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01) -
Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
by: Juliana Bentes Hughes, et al.
Published: (2012-06-01) -
Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
by: Azzurra Irelli, et al.
Published: (2024-01-01) -
Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)